Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05286801
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:57.762240+00:00
Published At
2026-04-13T00:00:00+00:00
Record Updated At
2026-04-13
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Atypical Teratoid/Rhabdoid Tumor", "Epithelioid Sarcoma", "Kidney Medullary Carcinoma", "Malignant Solid Neoplasm", "Poorly Differentiated Chordoma", "Recurrent Atypical Teratoid/Rhabdoid Tumor", "Recurrent Chordoma", "Recurrent Epithelioid Sarcoma", "Recurrent Kidney Medullary Carcinoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Rhabdoid Tumor", "Refractory Atypical Teratoid/Rhabdoid Tumor", "Refractory Chordoma", "Refractory Epithelioid Sarcoma", "Refractory Kidney Medullary Carcinoma", "Refractory Malignant Solid Neoplasm", "Refractory Rhabdoid Tumor", "Rhabdoid Tumor"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-13"
protocolSection.identificationModule.nctId
"NCT05286801"
protocolSection.identificationModule.officialTitle
"A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Atypical Teratoid/Rhabdoid Tumor (protocolSection.conditionsModule.conditions)
  • Epithelioid Sarcoma (protocolSection.conditionsModule.conditions)
  • Kidney Medullary Carcinoma (protocolSection.conditionsModule.conditions)
  • Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Poorly Differentiated Chordoma (protocolSection.conditionsModule.conditions)
  • Recurrent Atypical Teratoid/Rhabdoid Tumor (protocolSection.conditionsModule.conditions)
  • Recurrent Chordoma (protocolSection.conditionsModule.conditions)
  • Recurrent Epithelioid Sarcoma (protocolSection.conditionsModule.conditions)
  • Recurrent Kidney Medullary Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Recurrent Rhabdoid Tumor (protocolSection.conditionsModule.conditions)
  • Refractory Atypical Teratoid/Rhabdoid Tumor (protocolSection.conditionsModule.conditions)
  • Refractory Chordoma (protocolSection.conditionsModule.conditions)
  • Refractory Epithelioid Sarcoma (protocolSection.conditionsModule.conditions)
  • Refractory Kidney Medullary Carcinoma (protocolSection.conditionsModule.conditions)
  • Refractory Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Refractory Rhabdoid Tumor (protocolSection.conditionsModule.conditions)
  • Rhabdoid Tumor (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.